The intestinal expression of the CYP3A subfamily was investigated in female rats, and the intestinal metabolism of two CYP3A substrates, testosterone and rifabutin, was examined and compared between males and females. CYP3A1/23 and CYP3A2 intestinal expression was barely detected in male and female rats. Although CYP3A9 was predominantly expressed in the female rat liver, its expression in the intestine was not different between the two sexes. The rate of testosterone 6b b-hydroxylation in the female intestine was similar to that for males. Rifabutin was also metabolized at similar rates in both intestines, although the metabolic rate was greater in the female liver. These results indicate that the intestinal drug metabolizing activity of the CYP3A subfamily is similar between males and females, and that CYP3A9 is involved in the intestinal metabolism of CYP3A substrates in both sexes.
Cytochrome P450 (CYP) 3A4 is a human oxidative enzyme which is involved in the metabolism of various compounds. 1) CYP3A4 is expressed in the liver and to a lesser degree in the intestine.
2) Recently, it was reported that CYP3A4 in the intestine is an important factor that dominates the bioavailability of many medicines. [3] [4] [5] The immunosuppressant tacrolimus and a sedative midazolam are representative examples which are subjected to considerable intestinal first-pass metabolism when they are orally administered. 3, 6, 7) Therefore, it is necessary to examine to what extent intestinal drug metabolism contributes to their bioavailability, and to clarify whether the intestinal contribution is altered as a result of drug-drug interaction or disease.
The intestinal and hepatic metabolism of the CYP3A4 substrates has been frequently studied in rats. However, it should be noted that there are some peculiarities of drug metabolism in rats when bioavailability or drug-drug interactions are extrapolated to humans. 8) Previously, we found that the metabolic rates of CYP3A4 substrates in the intestine were poorly correlated with their metabolic rates in the liver in male rats. 9) Thus, the anti-tuberculosis drug, rifabutin is metabolized faster in intestinal tissues than other CYP3A4 substrates including lidocaine, quinidine, and nifedipine, although rifabutin is metabolized slowest in liver microsomes. One of the factors that contributes to this poor correlation is that CYP3A2 is dominantly expressed in the liver, while other members of the CYP3A subfamily (one of them likely being CYP3A9) are expressed in the intestine in male rats. 9, 10) The expression of the CYP3A subfamily is sex-dependent. CYP3A2 expression is strongly affected by androgens, 11) so that its expression is abolished in the castrated male rats. 12, 13) On the other hand, CYP3A9 expression is related to female sex hormones, 14, 15) and its hepatic expression is higher in females. 14, 16, 17) These findings suggest that the intestinal expression of CYP3A9 is also higher in females.
In this study, the intestinal expression of CYP3A9 in females was examined by Western blot analysis and was compared to that in males. As previously reported, 9) the expression of CYP3A9 can be detected by Western blotting with anti-CYP3A2 antibody, because CYP3A2 and CYP3A9 migrate at different rates under SDS-polyacrylamide gel electrophoresis and anti-CYP3A2 antibody cross-reacts to CYP3A9 due to the similarity of their C-terminuses (ThrVal-Asn-Gly-Ala-COOH for CYP3A9 and Val-Ile-Asn-GlyAla-COOH for CYP3A2). 9, 18, 19) CYP3A9 mRNA expression was also examined in the male and female intestines using the reverse transcription-polymerase chain reaction (RT-PCR). Furthermore, the intestinal metabolic rates of two CYP3A substrates, testosterone 1) and rifabutin 9, 20, 21) were determined in male and female rats, and the results were compared to clarify whether intestinal drug metabolism is carried out differently between the two sexes.
MATREIALS AND METHDOS

Materials
Testosterone and 6b-hydroxytestosterone were purchased from Nacalai Tesque (Kyoto, Japan) and Sigma-Aldrich Co. (St. Louis, MO, U.S.A.), respectively. Rifabutin was obtained from Research Diagnostic (Flanders, NJ, U.S.A.), and phenylmethylsulfonyl fluoride and trypsin inhibitor were acquired from Wako pure chemical (Osaka, Japan). Polyclonal antibodies against CYP3A1 and CYP3A2 were acquired from Chemicon International (Temecula CA, U.S.A.). These antibodies were raised against the C-terminus of CYP3A1/23 and CYP3A2, respectively, 18, 19) and since there is a considerable difference in their C-terminuses, the antibodies can distinguish CYP3A1/23 and CYP3A2 from each other. 9, 18, 19) CYP3A1 may be an allelic variant of CYP3A23. 16, 22) Therefore, we refer to them together as CYP3A1/23 in this report. CYP3A1 and CYP3A2 standard proteins were obtained from Daiichi Pure Chemicals (Tokyo, Japan). All other chemicals were of the finest grade available.
Animals Male and female Wistar rats (200-250 g body weight, 8-12 weeks of age) were purchased from Japan SLC Inc. (Hamamatsu, Japan). All animal experiments were performed in accordance with the guidelines for animal experiments of Toyama Medical and Pharmaceutical University.
Immunoblotting Analysis of the Intestinal and Hepatic
CYP3A Subfamily
The intestinal and hepatic expression of CYP3A1/23, CYP3A2, and CYP3A9 was evaluated by Western blot analysis. First, intestinal and liver microsomes were prepared from five rats in the same manner as previously reported. 9) The preparation was performed with icecold isotonic potassium phosphate buffer (pH 7.4) which contained 0.1 mM EDTA, 40 mg/ml phenylmethylsulfonyl fluoride and 0.5 mg/ml trypsin inhibitor. The obtained microsomes were suspended in distilled water. Then, 2 mg of liver microsomal protein were resolved by SDS-polyacrylamide (10%) gel electrophoresis. The applied protein amount was increased to 10 mg for intestinal microsomes. CYP3A1 and CYP3A2 standard proteins (50 fmol) were electrophoresed together. After that, they were transferred to a nitrocellulose membrane and incubated with antibody. The migration pattern was visualized, and the band signals were semi-quantitatively determined with densitometer. This Western blot analysis was carried out five times.
Hepatic and Intestinal Expression of CYP3A mRNA The intestinal and hepatic expression of rat CYP3A mRNA was examined using RT-PCR. After being anesthetized, liver and intestine were quickly excised. Excised liver was immediately minced, and then ground with a mortar and pestle which had been chilled by liquid nitrogen. Excised intestinal tissues were immediately washed with ice-cold 0.9% sodium chloride, and the mucosa of the jejunum was stripped off with a plate glass and collected. The mucosa was then ground in the same manner as the liver specimen. Ten milligrams were applied to an RNA extraction kit (QIAGEN, Valencia, CA, U.S.A.). The obtained RNA was stored at Ϫ20°C after its amount was spectrometrically determined. Three RNA specimens were collected individually for each sexes.
Reverse transcription was performed with 200 ng of pooled RNA specimen using an Omniscript TM reverse transcription kit (QIAGEN) according to the manufacture's instruction. The polymerase chain reaction was then conducted using a HotStarTaq ® PCR kit (QIAGEN). The annealing temperature was set at 61°C, and the cycle number was set at 26. Specific primers used for the amplification of each member of the CYP3A subfamily are listed in Table 1. 23) To detect CYP3A1/23 mRNA, a primer pair specific for the reported sequence of CYP3A23 mRNA was utilized.
23) bActin was used as an internal standard.
Following the polymerase chain reaction, 9 ml of the reaction mixture was resolved by electrophoresis on 3% agarose gel with Tris/borate/EDTA buffer (pH 8). The gel was then stained by 1 mg/ml ethidium bromide and the migration pattern was electromagnetically recorded.
Drug Metabolism in Liver Microsomes
The hepatic metabolism of testosterone and rifabutin were evaluated in liver microsomes as previously reported. 9) Testosterone was used at 300 mM to measure the rate of 6b-hydroxylation. Rifabutin was used at 2 mM. The incubation experiments were conducted with 2 mg and 800 mg of microsomal protein for testosterone and rifabutin, respectively. Following 5-min of pre-incubation, the metabolic reaction was initiated by adding a 100 ml of 10 mM NADPH solution to a 900 ml incubation mixture, which was prepared based on an isotonic potassium phosphate buffer (pH 7.4). The incubation was carried out for 20-30 min at 37°C, and the metabolic reaction was terminated by adding 5 ml of ice-cold diethyl ether. The metabolic rate of testosterone was evaluated as the formation rate of 6b-hydroxytestosterone, and that of rifabutin was calculated from the drug recovered after the incubation.
Drug Metabolism in Excised Intestinal Tissues
The intestinal metabolism of testosterone and rifabutin were examined using intestinal tissues according to a reported method, 9, 24, 25) in which the intestinal tissues were excised from rat jejunum and prepared as three of 10-cm segment. In brief, 300 mM testosterone or 2 mM rifabutin was incubated with excised intestinal tissues in 30 ml of isotonic sodium phosphate buffer (pH 7.4). After 60-min of incubation at 37°C, the incubation buffer and the tissues were collected, and the drug concentration was determined. The metabolic rate of testosterone was evaluated from the formation rate of 6b-hydroxytestosterone, and that of rifabutin was calculated from the drug amount recovered after incubation.
Analytical Methods 6b-Hydroxytestosterone and rifabutin were determined by HPLC as previously reported. 9, 25) In brief, the incubation mixture and tissue homogenate were extracted using diethyl ether. Then, the organic phase was collected and evaporated to dryness. The residue was dissolved in 500 ml of 50% methanol and injected to HPLC for determination. 6b-Hydroxytestosterone was eluted from TSK-GEL ® Super ODS column (TOSOH, Ayase, Japan) with 40% methanol and detected at the wavelength of 245 nm. Rifabutin was eluted from Develosil ® ODS-UG-3 column (Nomura Chemical, Seto, Japan) with 66% methanol-34% 10 mM potassium phosphate buffer (pH 2.5). Rifabutin was detected at 274 nm.
Data Analysis Data are shown as meansϮS.E. Significant differences were evaluated using the Student's t-test.
RESULTS
Intestinal and Hepatic Expression of CYP3A1/23 in Male and Female Rats
The intestinal and hepatic expression of the CYP3A subfamily was evaluated in female rats, and their expressions were compared to those in male rats. As shown in Fig. 1 , the band density of CYP3A1/23 in male rats was 68.2% of that of the CYP3A1 standard protein, 312 Vol Target  Forward  Reverse  Product size  Accession No.   CYP3A23  5Ј-GGAAATTCGATGTGGAGTGC-3Ј  5Ј-AGGTTTGCCTTTCTCTTGCC-3Ј  329  X96721  CYP3A2  5Ј-TACTACAAGGGCTTAGGGAG-3Ј  5Ј-CTTGCCTGTCTCCGCCTCTT-3Ј  348  NM_153312  CYP3A9  5Ј-GGACGATTCTTGCTTACAGG-3Ј  5Ј-ATGCTGGTGGGCTTGCCTTC-3Ј  373  NM_147206  CYP3A18 5Ј-TCCTGTCTCCAACCTTCACC-3Ј 5Ј-CACTCGGTTCTTCTGGTTTG-3Ј 413 NM_145782 b-Actin 5Ј-GAAGATCCTGACCGAGCGTG-3Ј 5Ј-CGTACTCCTGCTTGCTGATCC-3Ј 518 NM_031144
while that in female rats was 14.8% (Figs. 1A-C) . The hepatic CYP3A1/23 expression was 4.6 times higher in males (Table 2 ). CYP3A1/23 was only slightly expressed in intestine, but it seems to be expressed equally in males and females (Figs. 1D-F and Table 2 ). Fig. 2 , hepatic CYP3A2 expression was observed in male rats, while its intestinal expression was not detected in male or female rats. Hepatic CYP3A9 expression was detected in males and females, where it was found that CYP3A9 migrated slower than CYP3A2. The band density of CYP3A9 in liver microsomes was 9.5% of that of the CYP3A2 standard protein for males, while it was 41.4Ϯ5.1% for females ( Figs. 2A-C) , revealing that hepatic CYP3A9 expression was 4.3 times higher in females ( Table 2) . As for intestinal CYP3A9 expression, there was no difference between males and females (Figs. 2D-F and Table 2 ).
Intestinal and Hepatic Expression of CYP3A2 and CYP3A9 in Male and Female Rats As shown in
Intestinal and Hepatic Expression of CYP3A mRNA in Male and Female Rats The intestinal and hepatic expression of CYP3A mRNA was examined using RT-PCR. Messenger RNA of four members of the CYP3A subfamily was detected in male rats (Fig. 3A) . CYP3A1/23 and CYP3A9 were detected in female rat liver (Fig. 3C) . As for the intestinal expression of CYP3A mRNA, CYP3A9 mRNA was detected in males and females (Figs. 3B, D) . CYP3A9 mRNA expression in female intestine seems to be greater than that in male intestine (Figs. 3B, D) , though its protein expression is not different between males and females (Figs. 2D-F) . The reason for this discrepancy is unclear at present. Fig. 4 , testosterone 6b-hydroxylation in the liver microsomes occurred 10 times more slowly in females. Since the hepatic expression of CYP3A9 was higher in females ( Figs. 2A-C) , this suggests that CYP3A9 was less capable of mediating testosterone 6b-hydroxylation than CYP3A2 and CYP3A1/23. In contrast, testosterone 6b-hydroxylation in the intestine was not different between males and females (Fig. 4) . Protein detection was carried out with anti-CYP3A1 antibody. Liver microsomes (2 mg of protein) were applied in panels A, B, and C, and intestinal microsomes (10 mg of protein) were applied in panels D, E, and F. Each CYP3A1 (3A1) and CYP3A2 standard (3A2) was applied at 50 fmol. Representative 3 results in 5 experiments are shown for each of intestinal and hepatic expression studies. The proteins migrated in a downward direction.
Hepatic and Intestinal Metabolism of Testosterone in Male and Female Rats As shown in
Hepatic and Intestinal Metabolism of Rifabutin in
Fig. 2. Intestinal and Hepatic Expression of CYP3A2 and CYP3A9 in Male and Female Rats
Protein detection was carried out with anti-CYP3A2 antibody. Liver microsomes (2 mg of protein) were applied in panels A, B, and C, and intestinal microsomes (10 mg of protein) were applied in panels D, E, and F. Each CYP3A1 (3A1) and CYP3A2 standard (3A2) was applied at 50 fmol. Representative 3 results in 5 experiments are shown for each of intestinal and hepatic expression studies. The proteins migrated in a downward direction.
Male and Female Rats Rifabutin was metabolized 2.9 times faster in the female liver (Fig. 5) . As shown in Figs. 1  and 2 , the hepatic expression of CYP3A9 was higher in females, while those of CYP3A2 and CYP3A1/23 were higher in males. These results suggest that CYP3A9 may be partly responsible for rifabutin metabolism in rats. On the other hand, rifabutin was metabolized in the intestine at a similar rate in males and females (Fig. 5) . These findings are consistent with the observation that the intestinal expression profile of the CYP3A subfamily is the same between both sexes.
DISCUSSION
In this study, the intestinal expression of the CYP3A subfamily was investigated in female rats. The intestinal metabolism of the CYP3A4 substrates testosterone and rifabutin was also examined and the results were compared between males and females. CYP3A1/23 and CYP3A2 intestinal expression was barely or not detected in male and female rats (Figs.  1D-F and Figs. 2D-F) . The hepatic expression of CYP3A9 was predominant in the female rat liver, whereas its intestinal expression was not different between males and females (Fig. 2) . The intestinal and hepatic expression of CYP3A subfamily mRNA was also examined, and the results were consistent with those of the immunoblotting analysis, in which CYP3A9 mRNA was detected in the intestine in both sexes (Figs. 3B, D) . The rate of testosterone 6b-hydroxylation in the female intestine was similar to that in the male intestine (Fig. 4) . Rifabutin was also metabolized at a similar rate (Fig. 5) . These results indicate that the intestinal drug metabolizing activity of the CYP3A subfamily is similar between males and females, and that CYP3A9 is involved in the intestinal metabolism of CYP3A substrates in both sexes.
The hepatic expression of the rat CYP3A subfamily is sexdependent. In particular, CYP3A2 is expressed in a malespecific manner 1, 11) and CYP3A9 expression is related to an estrogen secretion.
14) Therefore, it is reasonable to expect that the intestinal expression of CYP3A9 is also predominant in female rats. However, this is not the case as shown in Figs.  1, 2, and 3 . Instead, the intestinal expression of the CYP3A subfamily was similar between males and females. This suggests that their expression in the intestine is regulated differently from that in the liver. Further studies are necessary to clarify the regulation mechanisms responsible for the intestinal and hepatic expression of the CYP3A subfamily in rats. For the catalytic activity of the CYP3A subfamily, testosterone 6b-hydroxylation in liver was insignificant in female rats. The rate of 6b-hydroxylation was 10 times slower in females (Fig. 4) , although hepatic CYP3A9 expression was higher in females (Figs. 2A-C and Table 2 ). In contrast, rifabutin was metabolized faster in female liver microsomes (Fig. 5) , although CYP3A2 was not detected in the female liver ( Figs. 2A-C) . These findings indicate that CYP3A9 does not readily catalyze testosterone 6b-hydroxylation, while it readily metabolizes rifabutin compared with CYP3A2. The substrate specificity of CYP3A9 is probably different from other members of the rat CYP3A subfamily.
As for intestinal drug metabolism, Koudriakova et al. reported that rifabutin is more readily metabolized in intestinal microsomes than in liver microsomes in rats. 21) We showed that rifabutin is metabolized by CYP3A9 and that CYP3A9 is dominantly expressed in the intestine (Figs. 2D-F and Table 2 ). These findings explain the reason why rifabutin is metabolized faster in the intestine than in the liver. CYP3A9 may play an important role in intestinal drug metabolism.
It is possible that unidentified member(s) of the CYP3A subfamily are expressed in an intestine-specific manner in rats. Gushchin et al. found that intestinal microsomes prepared from rats contain a cytochrome P450 that is similar to CYP3A1/23 and CYP3A2. 26) Sequence analysis indicated that the unidentified CYP3A isoenzyme was similar to CYP3A9. 26) Moreover, during the preparation of this report, Matsubara et al. reported the intestinal expression of CYP3A62, a novel member of the rat CYP3A subfamily. 27) According to their report, the overall similarity between CYP3A62 and CYP3A9 in terms of amino acid sequence is 79.9%. However, since the C-terminal sequence of CYP3A62 (Ala-Val-Ser-Arg-Asp-COOH) is different from that of CYP3A9 (Thr-Val-Asn-Gly-Ala-COOH), it is unlikely that the antibody used in this study cross-reacted with CYP3A62. Thus, we detected intestinal CYP3A9 expression as shown in Figs. 2D-F. CYP3A62 mediates testosterone 6b-hydroxylation at a rate similar to that of CYP3A9, while its N-deethylation activity for amiodarone and lidocaine is lower than that of CYP3A9. 27) Thus the drug metabolizing activity including involvement in rifabutin metabolism is probably different between CYP3A9 and CYP3A62. This will be clarified in future investigations.
In this study, we showed that CYP3A9 is primarily and sex-independently expressed in rat intestine. We also found that the intestinal metabolic rates of the CYP3A substrates testosterone and rifabutin are comparable between males and females. These findings provide important information which should be considered when the first-pass metabolism of CYP3A4 substrates is investigated in rats.
